Internal Medicine, Endocrinology, Diabetes, & Metabolism · Lexington, KY
NPI
1396857173
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
740 S Limestone
Lexington, KY, 40536
Phone (859) 323-5821
Groups this clinician bills Medicare through
Medicare paid, 2024
$2,555
44 services
Medicare patients, 2024
37
Average age 70
Drug cost, 2024
$2.5M
1,274 prescriptions
Company payments, 2025
$0
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kenneth B Ain was code 99215 (office e&m - established), 38 times for 36 patients. In total Kenneth B Ain billed 44 services in 3 codes, and Medicare paid $2,555.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-04-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 38 | 36 | $61.93 | $2,353 |
By year: 2022 $25K for 261 services; 2023 $16K for 189 services; 2024 $2,555 for 44 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kenneth B Ain prescribed most often to Medicare patients was Levothyroxine Sodium, with 519 prescriptions and refills. In total Kenneth B Ain wrote 1,274 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 519 | 1,360 | 179 | $7,659 |
| Amlodipine Besylate Generic | 102 | 220 | 33 | $498 |
| Calcitriol Generic | 80 | 170 | 27 | $1,667 |
| Metoprolol Succinate Generic | 74 | 206 | 29 | $985 |
| Losartan Potassium Generic | 64 | 186 | 26 | $652 |
| Lisinopril Generic | 64 | 180 | 26 | $478 |
| Sorafenib Sorafenib Tosylate | 43 | 43 | Under 11 | $468K |
| Hydrochlorothiazide Generic | 34 | 80 | Under 11 | $67.33 |
| Labetalol Hcl Generic | 29 | 87 | 13 | $1,192 |
| Mekinist Trametinib Dimethyl Sulfoxide | 26 | 26 | Under 11 | $425K |
| Lenvima Lenvatinib Mesylate | 24 | 24 | Under 11 | $499K |
| Tafinlar Dabrafenib Mesylate | 23 | 23 | Under 11 | $324K |
| Retevmo Selpercatinib | 22 | 22 | Under 11 | $489K |
| Atenolol Generic | 20 | 58 | Under 11 | $88.88 |
| Synthroid Levothyroxine Sodium | 18 | 38 | Under 11 | $1,739 |
Brand drugs: 413 claims; generic drugs: 861 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kenneth B Ain $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.